Marc Miravitlles1, Mònica Monteagudo2, Iryna Solntseva2, Bernardino Alcázar3. 1. Pneumology Department. Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Ciber de Enfermedades Respiratorias (CIBERES), Spain. Electronic address: marcm@separ.es. 2. Primary Care University Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain; Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Barcelona, Spain. 3. Ciber de Enfermedades Respiratorias (CIBERES), Spain; Respiratory Department, Hospital de Alta Resolución de Loja, Granada, Spain.
Abstract
BACKGROUND: There is controversy regarding the role of blood eosinophil levels as a biomarker of exacerbation risk in chronic obstructive pulmonary disease (COPD). Our aim was to quantify blood eosinophil levels and determine the risk of exacerbations associated with these levels and their variability. METHODS: Observational, retrospective, population-based study with longitudinal follow-up in patients with COPD identified in a primary care electronic medical record database in Catalonia, Spain, covering 80% of the general population. Patients were classified into 4 groups using the following cut-offs: (a) <150cells/μl; (b) ≥150 and <300cells/μl; (c) ≥300 and <500cells/μl; (d) ≥500cells/μl. RESULTS: A total of 57,209 patients were identified with a mean age of 70.2 years, a mean FEV1(% predicted) of 64.1% and 51.6% had at least one exacerbation the previous year. The number of exacerbations in the previous year was higher in patients with the lowest and the highest eosinophil levels compared with the intermediate groups. During follow-up the number of exacerbations was slightly higher in the group with the lowest blood eosinophil levels and in those with higher variability in eosinophil counts, but ROC curves did not identify a reliable threshold of blood eosinophilia to discriminate an increased risk of exacerbations. CONCLUSIONS: Our results do not support the use of blood eosinophil count as a reliable biomarker of the risk of exacerbation in COPD in a predominantly non-exacerbating population. Of note was that the small group of patients with the highest variability in blood eosinophils more frequently presented exacerbations.
BACKGROUND: There is controversy regarding the role of blood eosinophil levels as a biomarker of exacerbation risk in chronic obstructive pulmonary disease (COPD). Our aim was to quantify blood eosinophil levels and determine the risk of exacerbations associated with these levels and their variability. METHODS: Observational, retrospective, population-based study with longitudinal follow-up in patients with COPD identified in a primary care electronic medical record database in Catalonia, Spain, covering 80% of the general population. Patients were classified into 4 groups using the following cut-offs: (a) <150cells/μl; (b) ≥150 and <300cells/μl; (c) ≥300 and <500cells/μl; (d) ≥500cells/μl. RESULTS: A total of 57,209 patients were identified with a mean age of 70.2 years, a mean FEV1(% predicted) of 64.1% and 51.6% had at least one exacerbation the previous year. The number of exacerbations in the previous year was higher in patients with the lowest and the highest eosinophil levels compared with the intermediate groups. During follow-up the number of exacerbations was slightly higher in the group with the lowest blood eosinophil levels and in those with higher variability in eosinophil counts, but ROC curves did not identify a reliable threshold of blood eosinophilia to discriminate an increased risk of exacerbations. CONCLUSIONS: Our results do not support the use of blood eosinophil count as a reliable biomarker of the risk of exacerbation in COPD in a predominantly non-exacerbating population. Of note was that the small group of patients with the highest variability in blood eosinophils more frequently presented exacerbations.
Authors: Ramón Rabuñal; Roi Suarez-Gil; Rafael Golpe; Mónica Martínez-García; Raquel Gómez-Méndez; Eva Romay-Lema; Antía Pérez-López; Ana Rodríguez-Álvarez; Mercedes Bal-Alvaredo Journal: Telemed J E Health Date: 2020-06-04 Impact factor: 3.536
Authors: Allison J Burbank; Shannon D Lewis; Matthew Hewes; Dennis E Schellhase; Mallikarjuna Rettiganti; Julie Hall-Barrow; Lisa A Bylander; Rita H Brown; Tamara T Perry Journal: J Asthma Date: 2015-07-07 Impact factor: 2.515
Authors: José María Olaguibel; Santiago Quirce; Berta Juliá; Cristina Fernández; Ana María Fortuna; Jesús Molina; Vicente Plaza Journal: Respir Res Date: 2012-06-22
Authors: Nathan Hare; Priya Bansal; Sakina S Bajowala; Stuart L Abramson; Sheva Chervinskiy; Robert Corriel; David W Hauswirth; Sujani Kakumanu; Reena Mehta; Quratulain Rashid; Michael R Rupp; Jennifer Shih; Giselle S Mosnaim Journal: J Allergy Clin Immunol Pract Date: 2020-06-27
Authors: Dave Singh; Jadwiga A Wedzicha; Salman Siddiqui; Alberto de la Hoz; Wenqiong Xue; Helgo Magnussen; Marc Miravitlles; James D Chalmers; Peter M A Calverley Journal: Respir Res Date: 2020-09-17
Authors: Helgo Magnussen; Sarah Lucas; Therese Lapperre; Jennifer K Quint; Ronald J Dandurand; Nicolas Roche; Alberto Papi; David Price; Marc Miravitlles Journal: Respir Res Date: 2021-01-21
Authors: Irene Belmonte; Alexa Nuñez; Miriam Barrecheguren; Cristina Esquinas; Mònica Pons; Rosa M López-Martínez; Gerard Ruiz; Albert Blanco-Grau; Roser Ferrer; Joan Genescà; Marc Miravitlles; Francisco Rodríguez-Frías Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-10-07